FDA Clears LB2501 In Vivo CAR T Study

Company Legend Biotech Event Type Regulatory (FDA IND Clearance) Modality In vivo CAR-T; engineered lentiviral vector (TaVec platform) Asset LB2501 Target CD19; CD20 Disease Area Relapsed or refractory B-cell malignancies (including B-cell non-Hodgkin lymphoma) Summary FDA cleared Legend Biotech’s IND for LB2501, an investigational single-infusion…